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Abstract: OBJECTIVE: Narcolepsy with cataplexy is tightly associated with the HLA class II allele
DQB1*06:02. Evidence indicates a complex contribution of HLA class II genes to narcolepsy susceptibility
with a recent independent association with HLA-DPB1. The cause of narcolepsy is supposed be an
autoimmune attack against hypocretin-producing neurons. Despite the strong association with HLA
class II, there is no evidence for CD4+ T-cell-mediated mechanism in narcolepsy. Since neurons express
class I and not class II molecules, the final effector immune cells involved might include class I-restricted
CD8+ T-cells. DESIGN: HLA class I (A, B, and C) and II (DQB1) genotypes were analyzed in 944
European narcolepsy with cataplexy patients and in 4043 control subjects matched by country of origin.
All patients and controls were DQB1*06:02 positive and class I associations were conditioned on DQB1
alleles. RESULTS: HLA-A*11:01 (OR = 1.49 [1.18-1.87] P = 7.0*10-4), C*04:01 (OR = 1.34 [1.10-1.63]
P = 3.23*10-3), and B*35:01 (OR=1.46 [1.13-1.89] P = 3.64*10-3) were associated with susceptibility
to narcolepsy. Analysis of polymorphic class I amino-acids revealed even stronger associations with
key antigen-binding residues HLA-A-Tyr9 (OR = 1.32 [1.15-1.52] P = 6.95*10-5) and HLA-C-Ser11
(OR=1.34 [1.15-1.57] P = 2.43*10-4). CONCLUSIONS: Our findings provide a genetic basis for increased
susceptibility to infectious factors or an immune cytotoxic mechanism in narcolepsy, potentially targeting
hypocretin neurons.
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Study Objectives: Narcolepsy with cataplexy is tightly associated with the HLA class II allele DQB1*06:02. Evidence indicates a complex contribution 
of HLA class II genes to narcolepsy susceptibility with a recent independent association with HLA-DPB1. The cause of narcolepsy is supposed be an 
autoimmune attack against hypocretin-producing neurons. Despite the strong association with HLA class II, there is no evidence for CD4+ T-cell-mediated 
mechanism in narcolepsy. Since neurons express class I and not class II molecules, the final effector immune cells involved might include class I-restricted 
CD8+ T-cells.
Methods: HLA class I (A, B, and C) and II (DQB1) genotypes were analyzed in 944 European narcolepsy with cataplexy patients and in 4,043 control 
subjects matched by country of origin. All patients and controls were DQB1*06:02 positive and class I associations were conditioned on DQB1 alleles.
Results: HLA-A*11:01 (OR = 1.49 [1.18–1.87] P = 7.0*10−4), C*04:01 (OR = 1.34 [1.10–1.63] P = 3.23*10−3), and B*35:01 (OR = 1.46 [1.13–1.89] P = 3.64*10−3) 
were associated with susceptibility to narcolepsy. Analysis of polymorphic class I amino-acids revealed even stronger associations with key antigen-binding 
residues HLA-A-Tyr9 (OR = 1.32 [1.15–1.52] P = 6.95*10−5) and HLA-C-Ser11 (OR = 1.34 [1.15–1.57] P = 2.43*10−4).
Conclusions: Our findings provide a genetic basis for increased susceptibility to infectious factors or an immune cytotoxic mechanism in narcolepsy, 
potentially targeting hypocretin neurons.
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INTRODUCTION
Narcolepsy is a primary disorder of vigilance states character-
ized by episodes of unwanted sleep and sudden loss of muscle 
tone triggered by strong emotions (cataplexy). Although the 
HLA association found in 1984 led to the autoimmune hypoth-
esis of narcolepsy, it was only after the discovery of hypocretin 
(orexin) deficiency in 2000, due to the loss of hypocretin-
producing neurons, that the autoimmune hypothesis gained 
substantial basis.1–3 Nevertheless, convincing evidence of an 
autoimmune attack against hypocretin neurons is still lacking. 
Also, the nature of such autoimmunity remains elusive. The dis-
covery of auto-reactive antibodies against TRIB2 in a limited 
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Significance
Although evidence strongly indicates that immune-related mechanisms are involved in the pathogenesis of narcolepsy with hypocretin deficiency, 
functional data are missing. The strong association with HLA class II genes is not corroborated by any CD4+ T Cell implication and inflammation. 
Additionally, these genes are not normally expressed in the brain. Here, we show that several HLA class I variants are associated with narcolepsy. 
Since these molecules are expressed in the brain, our results suggest that a cytotoxic (CD8+ T Cell or NK cell) mechanism might be the final step in the 
disease, leading to hypocretin neuronal destruction.
number of narcolepsy patients suggested a humoral immune 
mechanism.4 As opposed to established and well-documented 
autoimmune disorders, T-cell-mediated autoimmunity has not 
yet been found in narcolepsy,5 except for rare cases of symp-
tomatic narcolepsy in which CD8+ T-cells may be pathogenic.6
By far major genetic susceptibility determinants of narco-
lepsy, as in other autoimmune disorders, are found within the 
HLA region.7,8 Among HLA class II genes, the DRB1*15:01-
DQA1*01:02-DQB1*06:02 is the disease-associated haplotype 
in narcolepsy. In European populations, the three alleles of 
this haplotype are in complete linkage disequilibrium (LD), 
so that any single allele is representative of the haplotype. 
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Early serologic typings in narcolepsy reported associations 
with HLA-B7 and A3 in Caucasian and B35 in Japanese pa-
tients.9–12 However, these original findings were subsequently 
interpreted as secondary (through LD) to HLA DRB1-DQB1 
association. Studies including molecular genotyping of HLA 
class I genes (A, B, and C) in large populations with narcolepsy 
are lacking. Nevertheless, a recent study used molecular HLA 
class I typing in 304 cases and 304 controls and imputed class 
I genotypes from previous genome-wide association studies 
(from HLA region SNP data) in White and Chinese popula-
tions.13 This study found (in addition to DPB1) significant as-
sociations between narcolepsy and HLA-A*11:01, B*35:03, and 
B*51:01.
HLA class II molecules are constitutively expressed only by 
antigen-presenting cells such as dendritic cells, macrophages, 
or B cells, while HLA class I molecules are ubiquitously ex-
pressed by nearly all nucleated cells. Accordingly, HLA class 
II molecules are not expressed by neurons while HLA class I 
molecules can be.14 Therefore, the ultimate autoimmune reac-
tion leading to neuronal cell death could involve HLA class 
I-restricted CD8+ reactive T-cells. Since HLA class I and II 
molecules are expressed by different cell types and shape dif-
ferent T-cell-mediated immune reactions, genetic associations 
to each HLA class bring different immunological information 
on the disease process, although the involvement of both is 
possible as exemplified in multiple sclerosis and type 1 dia-
betes.15,16 Thus the aim of the present study was to generate 
HLA class I genotyping data in narcolepsy with cataplexy and 
their matched controls and by controlling for the LD between 
HLA class I and the most important class II alleles, search for 
independent associations with HLA class I loci.
METHODS
Patients and Controls
Patients from the Netherlands (n = 334), France (n = 258), Ger-
many (n = 223), Switzerland (n = 67), and Poland (n = 62) were 
included in the analysis. Detailed description of these patients 
was recently published.7,17 All patients were HLA DQB1*06:02 
positive. Our populations did not include familial forms, sub-
jects with mixed non-European origin, or carrying rare (< 1%) 
DQB1 alleles (DQB1*03:04, DQB1*06:01, and DQB1*06:09). 
In 406 patients, genotypings were also generated for DRB1, 
DQA1, and DQB1 loci. Among these, DQB1*06:02 was in 
complete LD with DQA1*01:02 and with almost complete LD 
with DRB1*15:01 (403 out of 406, or 99.26%), confirming that 
DQB1*06:02 tags perfectly the narcolepsy-associated class II 
haplotype. Four-digit HLA-DQB1, A, B, and C genotyping was 
generated for all patients by PCR-Luminex. HLA DQB1*06:02 
positive controls were taken from panels of randomly selected, 
healthy, representative, and unrelated Dutch (n = 2,158), French 
(n = 583), German (n = 559), Swiss (n = 570), and Polish/Slovak 
(n = 173) subjects.
Linkage Disequilibrium and Haplotype Construction
To evaluate the LD between DQB1 and A, B, and C loci, 736 
French and 1,239 Dutch control subjects from the general pop-
ulation (unselected by DQB1 genotype) were used. Haplotype 
frequencies and phase segregations of four-loci alleles (HLA-A, 
B, C and DQB1) were inferred from merged population data set 
of unphased genotypes observed in the patients and controls as 
described previously.18 Briefly, four-loci unphased genotypes 
were automatically encoded (and haplotypes were decoded 
afterwards) using PHASE_KEY v.1.0 (software available at 
http://www.ihit.waw.pl/zaklad-immunogenetyki.html). The 
most probable four-loci haplotype segregations were estab-
lished for all patients and controls using Bayesian implementa-
tion of expectation maximization (EM) algorithm provided by 
PHASE v. 2.1.19 The iterative processing involved burn-in it-
erations set to 200 and 1,000 final iterations. Informed consent 
was obtained from all subjects and the experimental protocols 
were approved by each country’s ethics institution.
Statistical Analysis
Associations between HLA class I alleles and narcolepsy, in-
dependent of HLA class II (DQB1) alleles were tested by the 
Cochran-Mantel-Haenszel test.20 To ensure the robustness 
of our findings, two additional tests were performed: (1) for 
each class I allele we performed logistic regression including 
all DQB1 alleles as covariates; (2) we also performed logistic 
regression for each class I allele, stratifying our samples ac-
cording to DQB1 alleles. These stratified results were then 
meta-analyzed using fixed effect inverse variance weighting. 
We also applied Cochran’s heterogeneity test for the results of 
all countries to ensure that our findings hold irrespective of 
the origin of the samples. Our major findings were confirmed 
by these additional analyses and no cross-cohort heterogeneity 
was detected. Thus we present the results for the Cochran-
Mantel-Haenszel test only. The analysis was restricted to Class 
I alleles with allele frequencies > 0.5% in at least one control 
sample and to alleles detected in all countries. We estimated 
the effective number of tests (i.e., the equivalent number of 
independent alleles by taking into account the LD between al-
leles) as proposed by Gao et al.21 The 45 A, B, and C alleles 
tested are equivalent to 29 independent tests, thus we used the 
modified Benjamini-Hochberg step-up procedure for 29 tests 
to control the false discovery rate (FDR) at 5%.
RESULTS
Single HLA Class I Allele Association
The frequency of the 45 class I alleles tested is reported in 
Table S1 (supplemental material). Although in many studies, 
control subjects are just matched for ethnicity (e.g., of Euro-
pean descent), substantial differences in HLA allele frequen-
cies are commonly observed between sub-populations and 
even within the same country. Allele frequency heteroge-
neity test indicated that 15 of the 45 alleles show significant 
between-country heterogeneity (Table S1). We therefore tested 
for allelic associations independently in each country with their 
matched controls. Since we have matched our control popula-
tions for DQB1*06:02, we first tested HLA class I associations 
with narcolepsy without correcting for LD with HLA class II 
(DQB1) alleles (Table S2, supplemental material). As opposed 
to DQB1*06:02 unmatched controls, associations with known 
alleles with strong LD with DQB1*06:02 (e.g., B*07:02 and 
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C*07:02; Figure 1) were strongly attenuated. Nevertheless, 
other narcolepsy-associated DQB1 alleles (DQB1*02, *03:01, 
*05:01, and *06:03) with potential LD with class I alleles might 
bias these results.
By taking into account all DQB1 alleles, Cochran-Mantel-
Haenszel test revealed significant DQB1-independent asso-
ciations with HLA-A*11:01, C*04:01, and B*35:01. All three 
alleles increased the risk of narcolepsy (Table 1). The two other 
analyses (conditional and stratified) confirmed these associa-
tions and additionally indicated a protective association con-
ferred by B*08:01 (Tables S3 and S4, supplemental material). 
The associations with C*04:01, and B*35:01 are consistent 
with high LD between these 2 alleles (Figure 2). Accordingly, 
conditional analysis indicated 2 independent associations, one 
with A*11:01 and the other with C*04:01 or B*35:01. Also, as-
sociations with B*08:01 and potentially with A*01:01 might be 
due to LD between these 2 alleles (Figure 2), which are part 
of the extended conserved haplotype known as “A1-B8-DR3,” 
or “8.1.” The complete class II-independent associations with 
HLA-A*11:01, C*04:01, and B*35:01 are demonstrated by the 
fact that these alleles occurred in all DQB1 haplotypes and 
even less frequently in at risk DQB1 alleles carriers (Table 2).
HLA Class I Haplotype Association
To verify if our allelic associations may result from extended 
haplotypes, the class I haplotypes (HLA-A, B, C) and ex-
tended four-loci haplotypes (HLA-A, B, C and DQB1) were 
compared between cases and controls from each country. 
The class I A*11:01-C*04:01-B*35:01 haplotype had no sta-
tistically different incidence in cases and controls (2.7% and 
2.2%, respectively, OR = 1.25, [0.77–2.03], P = 0.36), con-
firming the independent allelic associations. Three extended 
haplotypes were significantly associated: A*03:01-C*04:01-
B*35:01-DQB1*06:02 (OR = 2.39 [1.35–4.22], P = 2.80*10−3), 
A*03:01-C*04:01-B*35:01-DQB1*05:01 (OR = 0.02 [0.00–
0.16], P = 9.41*10−4), A*03:01-C*07:02-B*07:02-DQB1*06:02 
(OR = 0.72 [0.58–0.90], P = 3.11*10−3). The increased sus-
ceptibility to narcolepsy in carriers of A*03:01-C*04:01-
B*35:01-DQB1*06:02 haplotype can be attributed to its 
allele components due to independent associations of C*04:01, 
B*35:01 and DQB1*06:02. Interestingly, the protective 
A*03:01-C*04:01-B*35:01-DQB1*05:01 haplotype including 
the risk alleles C*04:01 and B*35:01 was not found in any pa-
tient. The protective property of A*03:01-C*07:02-B*07:02-
DQB1*06:02 haplotype is not straightforward. It may protect 
from narcolepsy by the involvement of class III genes of an-
cestral haplotype or DPB1 alleles (not tested here), discordant 
peptide presentation repertoires between class I and class II 
alleles and clonal deletion of some naïve thymocytes and/or 
involvement of protective DQB1 alleles in trans.
HLA Class I Epitope Association
One major limitation of HLA class I allelic association is the 
large number of alleles (here 190 alleles) that decreases the sta-
tistical power, therefore limiting the analysis to the most fre-
quent alleles (here 45 alleles). Additionally, this analysis does 
not take into account shared epitopes among alleles, which 
are actually responsible for antigen presentation. To overcome 
these limitations, we analyzed HLA class I polymorphic 
amino acids associated with susceptibility and resistance to 
narcolepsy with cataplexy. Several HLA class I amino acids 
were found associated with narcolepsy, independently of HLA 
class II (Table 3). These associations were stronger than allelic 
associations. By searching for alleles that best tag significant 
amino-acid associations, again A*11:01, B*35:01, and C*04:01 
were identified, confirming our allele frequency analysis 
(Table 3). Interestingly, based on crystal structure of HLA-A, 
B, and C, several of these associated amino acids are of notable 
functional importance (Figure 3). HLA-A-Tyr9, Ala152, Arg163, 
HLA-B-Glu76, HLA-C-Ser9, Ser11, Phe99, and Arg156 are found 
in the peptide-binding grove. HLA-A-Arg163 and HLA-B-Glu76 
can affect T cell receptor (TCR) recognition and HLA-B-Glu76 
can interact with killer immunoglobulin receptors. Among 
Figure 1—Linkage disequilibrium between HLA-DQB1 and HLA class 
I alleles in the general population. Heat map of linkage disequilibrium 
between HLA-DQB1 and HLA-A, B, C alleles analyzed in combined 
Dutch and French general population unselected for DQB1*06:02. Major 
significant LD values are indicated.
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OR (95% CI) P
A*11:01 1.25 1.96 1.25 2.00 1.65 1.49 (1.18–1.88) 7.00E-04
C*04:01 1.33 1.39 1.13 1.70 1.23 1.34 (1.10–1.63) 3.23E-03
B*35:01 1.47 1.67 1.21 1.41 1.41 1.46 (1.13–1.89) 3.64E-03
C*07:01 0.87 0.76 0.88 0.58 1.03 0.83 (0.68–1.01) 5.73E-02
A*01:01 0.89 0.69 0.87 0.60 1.73 0.84 (0.70–1.01) 6.21E-02
B*56:01 1.35 7.87 1.85 1.63 0.81 2.12 (0.92–4.91) 7.78E-02
A*25:01 1.01 1.60 1.63 0.42 0.86 1.33 (0.95–1.86) 9.43E-02
B*08:01 0.85 0.73 0.97 0.34 1.23 0.82 (0.64–1.05) 1.20E-01
A*29:02 0.74 0.65 1.23 0.30 0.70 0.67 (0.41–1.11) 1.21E-01
C*01:02 1.08 1.98 0.99 1.18 2.72 1.43 (0.88–2.31) 1.46E-01
P values in bold survive Benjamini-Hochberg false discovery rate controlled at 5%. Numbers below country codes indicate number of patients-to-controls. 
NL, Netherlands; FR, France; DE, Germany; CH, Switzerland; PL, Poland/Slovakia; CMH, Cochran-Mantel-Haenszel; OR (95% CI), odds ratio (95% 
confidence interval).
Figure 2—Linkage disequilibrium between HLA class I alleles in the general population. Heat map of linkage disequilibrium between HLA-A, B, and C 
alleles analyzed in combined Dutch and French general population unselected for DQB1*06:02. Major significant LD values are indicated.
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Figure 3—Key narcolepsy-associated HLA class I residues positioned on crystal structures. HLA and β2-microglobulin are shown in ribbon representation, 
colored in brown and blue, respectively. Epitopes are displayed in ball and stick representation, colored according to the atom types. Important HLA 
residues are displayed as spheres, colored according to the atom types except for orange carbon atoms. The figure was prepared with UCSF Chimera28, 
using the Protein Databank29 entries 1X7Q30 (HLA-A*11:01), 3LKO31 (HLA-B*35:01), and 1IM932 (HLA-C*04:01).
Table 2—Percentage of class I positive samples carrying protective, risk, or neutral DQB1 alleles. 
Patients
Protective Risk Neutral
DQB1*02, *05:01,*06:03 DQB1*03:01, *06:02 DQB1*03:02, *03:03, *04:02, *05:02, *05:03, *06:04
A*11:01 27.07% 40.60% 32.33%
C*04:01 30.77% 31.87% 37.36%
B*35:01 30.19% 35.85% 33.96%
Controls
Protective Risk Neutral
DQB1*02, *05:01,*06:03 DQB1*03:01, *06:02 DQB1*03:02, *03:03, *04:02, *05:02, *05:03, *06:04
A*11:01 33.74% 34.24% 32.02%
C*04:01 46.24% 29.31% 24.45%
B*35:01 51.94% 25.84% 22.22%
Counts are reported separately for narcolepsy patients and controls.
Table 3—Odds ratios for HLA class I amino-acids significantly associated with narcolepsy independent of HLA-DQB1 alleles.
Amino-Acid OR-NL OR-FR OR-DE OR-CH OR-PL CMH OR (95% CI) P ABC-Tag r2
HLA-A-Y9 1.15 1.59 1.29 1.64 1.21 1.32 (1.15–1.52) 6.95E-05 A*11:01 0.32
HLA-A-D90 1.15 1.67 1.44 1.34 0.99 1.33 (1.13–1.55) 4.68E-04 A*11:01 0.48
HLA-A-P105 1.21 1.51 1.45 1.36 0.96 1.32 (1.15–1.52) 8.12E-05 A*11:01 0.35
HLA-A-A152 1.24 1.84 1.30 2.00 1.65 1.46 (1.18–1.80) 5.04E-04 A*11:01 0.98
HLA-A-R163 1.17 1.65 1.42 1.34 0.99 1.32 (1.13–1.55) 5.22E-04 A*11:01 0.48
HLA-B-T45 1.08 1.38 1.21 1.84 1.04 1.24 (1.10–1.41) 7.87E-04 B*51:01 0.25
HLA-B-V103 0.92 0.77 0.73 0.67 0.56 0.78 (0.68–0.90) 9.09E-04 B*35:01 0.32
HLA-B-I194 0.82 0.79 0.80 0.47 0.64 0.75 (0.65–0.86) 8.17E-05 B*51:01 0.37
HLA-B-V194 1.21 1.20 1.20 1.97 1.45 1.28 (1.11–1.48) 8.04E-04 B*51:01 0.38
HLA-C-S9 1.31 1.33 1.19 1.50 1.57 1.32 (1.12–1.57) 1.24E-03 C*04:01 0.86
HLA-C-A11 0.78 0.64 0.96 0.62 0.55 0.74 (0.63–0.86) 1.18E-04 C*04:01 0.64
HLA-C-S11 1.28 1.45 1.15 1.46 1.82 1.34 (1.10–1.57) 2.43E-04 C*04:01 0.68
HLA-C-R14 0.76 0.65 1.01 0.52 0.82 0.75 (0.63–0.89) 1.39E-03 C*04:01 0.92
HLA-C-W14 1.32 1.37 1.13 1.71 1.23 1.32 (1.10–1.58) 2.77E-03 C*04:01 1.00
HLA-C-A49 0.76 0.65 1.01 0.52 0.82 0.75 (0.63–0.89) 1.39E-03 C*04:01 0.92
HLA-C-E49 1.32 1.37 1.13 1.71 1.23 1.32 (1.10–1.58) 2.77E-03 C*04:01 1.00
HLA-C-F99 1.33 1.34 1.19 1.50 1.57 1.33 (1.12–1.58) 8.92E-04 C*04:01 0.85
HLA-C-R156 1.29 1.23 0.98 1.19 2.13 1.23 (1.08–1.40) 2.11E-03 C*04:01 0.39
All P values survive Benjamini-Hochberg false discovery rate controlled at 5%. ABC-Tag, the best HLA class I allele tagging each amino-acid with r2 
values; NL, Netherlands; FR, France; DE, Germany; CH, Switzerland; PL, Poland/Slovakia; CMH, Cochran-Mantel-Haenszel; OR (95% CI), odds ratio 
(95% confidence interval). 
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these amino acids several are found within the same HLA 
alleles and therefore closely associated. Accordingly, condi-
tional analysis revealed strong associations only with HLA-A-
Tyr9 (OR = 1.32 [1.15–1.52], P = 6.95*10−5) and HLA-C-Ser11 
(OR = 1.34 [1.15–1.57] P = 2.43*10−4).
DISCUSSION
The tight association between the HLA class II DQB1*06:02 
allele and narcolepsy with cataplexy is well established and the 
original associations with class I genes, such as B7 specificity, 
are definitely due to high LD between DQB1*06:02 and class 
I alleles such as B*07:02 (Figure 1). Nevertheless, the associa-
tion is much stronger with DQB1 locus since B*07:02 does not 
occur in all DQB1*06:02-associated haplotypes (association 
with DQB1*06:02 is found in over 98% while B*07:02 is found 
in less than 65% of narcolepsy patients). In addition to LD be-
tween class I and II genes, finding associations with class I 
genes is hampered by a large number of class I alleles, requiring 
large patient populations, unavailable in rare disorders like 
narcolepsy. By controlling for LD, we identified HLA-A*11:01, 
B*35:01, and C*04:01 as new narcolepsy susceptibility alleles. 
Conditioned and unconditioned results very strongly agreed for 
A*11:01. However, the signal from B*35:01 and C*04:01 could 
not be resolved: conditioning on each other gave nonsignificant 
results both ways (P > 0.3). Since B*35:01-C*04:01 haplotype 
is the fourth most common haplotype in our control population 
we cannot decide which allele is actually causal.
In our previous paper,7 we examined the association of 
class II alleles with narcolepsy in largely overlapping samples 
and (except for the DQB1*06:02) found that several class II 
alleles have strong protective effects (OR = 0.19–0.76) while 
the class I alleles described here are markers of susceptibility 
(ORs ranging 1.34–1.49). Note that class I associations not con-
ditioned on DQB1 alleles show much larger effect sizes (see 
Table S2).
Although our study is so far one of the largest ones, including 
944 patients, we obviously lack statistical power to detect all 
potential narcolepsy-associated HLA class I alleles. We there-
fore speculate that the HLA class I alleles found here to be 
suggestively associated with narcolepsy might turn out to be 
significant in larger samples. Association with HLA-A*11:01 
was also reported recently, together with suggestive association 
with C*04:01.13 Nevertheless, associations with HLA-B*35:03 
and B*51:01 found previously are not replicated by our results. 
While both alleles have similar frequencies in our populations 
and those of Ollila et al.,13 we only found them marginally 
significant (with similar ORs) in the unconditioned analysis. 
Hence we suspect that these associations are not robust to con-
ditioning on DQB1 alleles or they may have different LD in our 
populations. On the other hand, our associations with B*35:01 
and B*08:01 were not reported before. The former had similar 
frequencies in the imputed genotypes of Caucasians in Ollila 
et al.,13 but different ones in their typed samples. The latter 
showed opposite behavior, following our trend in the directly 
typed samples and discrepant frequencies in the imputed ones. 
Thus, Ollila et al.,13 may have missed some of our findings due 
to their possibly poor allele imputation, or different allelic fre-
quencies between controls in the two studies.
The strongest genetic association with autoimmune diseases 
is found with HLA class II alleles. Nevertheless, recent studies 
reported convincing evidence for independent associations 
with class I alleles in several autoimmune disorders such as 
type 1 diabetes and multiple sclerosis.15,16 The implication of 
class I genes in autoimmune diseases may help to understand 
the underlying immune mechanisms. CD4+ T-cells are HLA 
class II-restricted and mediate the production of cytokines 
such as interleukins and TNF-α, resulting in inflammation 
and promotion of B- and T- cell activation and differentiation, 
while CD8+ T-cells are HLA class I-restricted and are respon-
sible for killing of virally infected or tumor cells, as well as 
transplant rejection. Although the HLA class II associations 
led to extensive work on CD4+ T-cell autoreactivity in autoim-
mune disorders, evidence strongly supports also a critical role 
for CD8+ T-cells that can modulate the immune response ei-
ther directly through cytotoxic killing of cells or by regulatory 
(protective) mechanisms.22
The most specific narcolepsy allele DQB1*06:02 is the 
strongest protective allele in type 1 diabetes. Interestingly, 
A*11:01, and C*04:01 found here as risk alleles for narcolepsy 
are protective in type 1 diabetes,15 suggesting an exclusive 
HLA contribution to these two conditions. The susceptibility 
association with single class I alleles found here points to the 
main HLA function, the better presentation of tissue specific 
peptides within peptide presentation repertoires of class I-as-
sociated alleles. Physiologically, HLA class I and II molecules 
present mostly self-peptides that are recognized by naive T 
cells with low/intermediate affinity of their TCR for the MHC-
peptide complex.23 The process is regulated by peptide presen-
tation repertoires partly overlapping between HLA molecules 
24 and tight selection of thymocytes directed to promiscuous 
tissue-specific peptides expressed in the thymus.25 Presenta-
tion of slightly modified peptides and generation of CD8+ T 
cell clones with increased affinity of TCR for MHC-peptide 
(above the activation threshold) is needed to induce a cytotoxic 
attack.26 These observations indicate a crucial role of HLA 
peptide presentation repertoires in both the scope of thymic 
selection and the induction of T-cell cytotoxicity. Class I allelic 
associations in DQB1*06:02 positive populations may point to 
the relation between class I and class II peptide repertoires. 
This suggests that peptide presentation repertoires of associ-
ated class I molecules fall within the framework of primarily 
associated class II molecule repertoire, thus shaping the cy-
totoxic attack, presumably specific to hypocretin-producing 
neurons. A T-cell clone with such a narrow specificity can be 
prone to clonal deletion in certain class I/II combinations.
Also, HLA class I-encoded molecules interact with killer 
immunoglobulin-like receptors, mostly expressed on natural 
killer cells and a subset of memory T cells to provide inhibi-
tory signals. Our finding that A*11:01 and C*04:01 increase the 
risk of narcolepsy with cataplexy not only provides a genetic 
basis for a cell-mediated mechanism but also suggests a poten-
tial immune pathway critically involving natural killer cells. 
Also, leukocyte Ig-like receptors (LILRs) bind class I mole-
cules and can modify the antigen presentation by macrophages 
and dendritic cells. The activating LILRA1 and LILRA3 re-
ceptors (CD85) bind preferentially the HLA-C heavy chain27 
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and modulate T-cell proliferation. Whether C*04:01-restricted 
CD8+ T-cells occur in narcolepsy patients needs further 
investigations.
In conclusion, the discovery of independent HLA class 
I associations with narcolepsy provides the first genetic evi-
dence that a direct CD8 and/or NK-mediated immune reaction, 
potentially targeting hypothalamic hypocretin neurons, can 
occur in this disease.
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